KalVista Bundle
Who owns KalVista Pharmaceuticals?
KalVista rose to prominence in 2024–2025 after positive Phase 3 sebetralstat data and a commercialization-focused capital raise, shifting its shareholder mix. Founded in 2011 in Oxford with US HQ in Cambridge, MA, the company targets plasma kallikrein–mediated diseases.
Today KalVista is a widely held public biotech: significant institutional investors and biotech funds, meaningful insider stakes, and a public float anchored by recent funding moves. See KalVista Porter's Five Forces Analysis for strategic context.
Who Founded KalVista?
Founders and early ownership of KalVista Pharmaceuticals trace to a 2011 U.K. launch led by Andrew Crockett (co‑founder and long‑time CEO) with scientific co‑founder Christopher J. D. Whitfield and academic collaborators from the Oxford/Cambridge protease biology ecosystem; initial equity was split among founders, a seed syndicate and an employee option pool typical for U.K. biotech.
Founding team
Andrew Crockett served as commercial and executive lead while Christopher Whitfield provided scientific co‑founder expertise rooted in plasma kallikrein biology.
Academic links
Early scientific leadership included researchers tied to Oxford and Cambridge protease programs focused on kallikrein and contact pathway biology.
Initial cap table
Detailed founding percentages were not publicly disclosed; founders and scientific contributors held a minority stake post‑seed under typical 4‑year vesting with a 1‑year cliff and reverse vesting/buy‑back clauses.
Seed and Series A backers
Notable early investors included SV Health Investors, Novo Holdings (Novo A/S), Longwood Fund and Oxford angels participating in seed/Series A preferred rounds.
Investor rights
Early rounds implemented convertible notes and preferred equity with anti‑dilution, pro rata rights, investor protective provisions, board seats and veto rights on major corporate actions.
Dilution and employee pool
Subsequent financings and the 2017 U.S. IPO diluted founder stakes while expanding the employee equity pool to support R&D hiring and retention.
Early ownership established the framework for KalVista Pharmaceuticals ownership and KalVista shareholders composition that evolved through institutional rounds and public listing activity.
Key facts at founding and early rounds
Founders and early investors set the company's governance and protective terms; public disclosures after IPO show shifting institutional ownership.
- Founding year: 2011
- Typical founder vesting: 4‑year schedule with 1‑year cliff
- Notable early investors: SV Health Investors, Novo Holdings, Longwood Fund, Oxford angels
- IPO: U.S. public listing in 2017 led to founder dilution and expanded employee option pool
For linkage to the company's revenue and business model context see Revenue Streams & Business Model of KalVista
KalVista SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has KalVista’s Ownership Changed Over Time?
Key financing milestones — seed/Series A backers (SV Health, Novo A/S), the 2017 NASDAQ reverse merger, Merck collaboration, follow-on offerings (2021–2024), and positive Phase 3 KONFIDENT results — drove KalVista Pharmaceuticals ownership from concentrated venture control to a broadly held institutional register by mid-2025.
| Period | Ownership dynamics | Notable stakeholders |
|---|---|---|
| 2011–2016 | Seed/Series A established initial control; investors obtained board seats and preferred terms | SV Health Investors, Novo A/S, allied life science funds |
| 2017 (IPO via reverse merger) | Public listing through Carbylan Therapeutics reverse merger; legacy KalVista shareholders retained majority | Venture holders, insiders; pro forma market cap in the low $100s million |
| 2017–2020 | Non-dilutive strategic collaboration provided funding without equity transfer; option later terminated | Merck (MSD) — strategic partner, no lasting equity stake |
| 2021–2023 | Follow-on equity raises to fund HAE programs; institutional holders increased | RA Capital, FMR LLC/Fidelity, BVF Partners, venBio, Perceptive Advisors; insiders collectively high single digits–low teens % |
| 2024–mid‑2025 | Equity raises post-KONFIDENT to fund commercialization; broader public float, no single controller | Fidelity (FMR LLC), RA Capital, BVF, BlackRock, Vanguard; insiders meaningful but non‑controlling; market cap ~$1.0–1.5B |
Investor mix evolution shifted KalVista Pharmaceuticals ownership from concentrated venture capital control to diversified institutional and retail holdings, supporting capital needs for CMC, medical affairs, and commercial readiness while aligning governance with public-market norms; see further context in the Target Market of KalVista article.
Ownership snapshot (mid‑2025)
Top institutional holders and insider ranges reflect a non‑controlling but significant insider stake and broad institutional ownership.
- Major institutional investors include Fidelity (FMR LLC), RA Capital, BVF Partners, BlackRock, Vanguard
- Insiders (management + directors) typically hold high single digits to low teens % collectively
- No single controlling shareholder; public float expanded after multiple offerings
- Market cap ranged around $1.0–1.5 billion depending on biotech market sentiment and HAE launch expectations
KalVista PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on KalVista’s Board?
As of 2024–2025 KalVista Pharmaceuticals' board is chaired and led operationally by Andrew Crockett (CEO and co‑founder) alongside a slate of independent directors with clinical, commercial and finance backgrounds; investor‑affiliated directors have historically reflected early backers such as SV Health Investors and Novo Holdings.
| Director | Role / Affiliation | Notes on Voting Influence |
|---|---|---|
| Andrew Crockett | CEO, Co‑founder | Management representative; one‑share‑one‑vote implies standard voting weight |
| Independent Industry Veteran(s) | Clinical / Commercial Experts | Provide independent oversight; key to committee votes (audit/comp) |
| Investor‑Affiliated Director(s) | Representatives linked to early backers | Historically connected to SV Health Investors, Novo Holdings; seats may rotate |
KalVista operates on a one‑share‑one‑vote capital structure with no dual‑class or founder/golden shares reported in recent proxy filings; voting power is dispersed across institutional holders rather than concentrated with a single insider.
Board and Voting Highlights
Institutional ownership and proxy advisor recommendations materially shape outcomes for director elections, say‑on‑pay and equity plan approvals.
- Proxy filings show no dual‑class shares; governance follows one‑share‑one‑vote
- Top 10–15 shareholders and ISS/Glass Lewis guidance typically determine contested votes
- No material proxy contests or activist campaigns reported through 2025
- Equity compensation and share authorizations have passed with customary biotech support levels, supporting sebetralstat development
For additional company context see Mission, Vision & Core Values of KalVista.
KalVista Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped KalVista’s Ownership Landscape?
From 2022 through mid‑2025 KalVista Pharmaceuticals ownership shifted toward broader institutional ownership after multiple follow‑on equity offerings; dilution of early stakes was offset by a stronger balance sheet to fund NDA/MAA filings and launch preparation.
| Period | Key ownership change | Impact |
|---|---|---|
| 2022 follow‑ons | Equity raises increased public float; crossover funds entered pre‑commercial stage | Improved cash runway for regulatory filings; earlier holders diluted |
| 2023–2024 | Continued secondary offerings; modest index inclusion (Russell reconstitutions) | Passive ownership rose via BlackRock/Vanguard; institutional concentration increased |
| 2024–H1 2025 | Targeted raises to fund NDA/MAA and launch readiness; insider trades mainly exercises and 10b5‑1 sales | No material insider disposals; governance shaped by institutional holders |
Industry trends show late‑stage biotech moving to higher institutional concentration and crossover investor participation; KalVista lacks a strategic corporate cornerstone investor, leaving options for independent launch, ex‑US partnering, or acquisition contingent on sebetralstat approval and uptake.
Capital raises and balance sheet
Follow‑ons from 2022–2025 increased cash to support NDA/MAA filings and early launch spend; management states runway into commercialization without forcing dilutive actions.
Insider ownership and transactions
Insider transactions were predominantly option exercises and scheduled 10b5‑1 sales; no large insider disposals signaled negative insider sentiment in 2024–2025.
Institutional ownership trends
By 2025 institutional ownership increased, with major asset managers and crossover funds forming the largest blocks; passive ETFs contributed modestly via index inclusion.
Strategic optionality
Absent a strategic equity holder, KalVista retains flexibility: independent commercialization, regional partnerships, or a potential buyout if sebetralstat reaches target market penetration.
Analysts in 2024–2025 noted that successful approval of sebetralstat could unlock partnership non‑dilutive capital or an acquisition opportunity given HAE branded therapy markets frequently exceed $100m to $1bn+ annually; see further context in Marketing Strategy of KalVista.
KalVista Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of KalVista Company?
- What is Competitive Landscape of KalVista Company?
- What is Growth Strategy and Future Prospects of KalVista Company?
- How Does KalVista Company Work?
- What is Sales and Marketing Strategy of KalVista Company?
- What are Mission Vision & Core Values of KalVista Company?
- What is Customer Demographics and Target Market of KalVista Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.